Tirzepatide appetite suppression: what the science actually shows

The biggest misconception: tirzepatide does not simply turn hunger off

The most common misunderstanding a question our prescribers hear most weeks is this: that tirzepatide works like a switch, eliminating appetite entirely from day one. It does not. What it does is alter the quality and timing of hunger signals. Most people find that meals feel filling after much smaller portions, that the urge to snack between meals fades, and that food (particularly very rich or fatty food) becomes less compelling. But hunger does not disappear; it becomes easier to manage.

This matters because people who expect complete appetite elimination sometimes assume the medicine is not working when it is. The starter dose of 2.5mg exists to help your body adjust, not to deliver the full therapeutic effect. The appetite-suppressing effect tends to build as the dose is titrated upward by the prescriber. If you are on an early dose and finding the hunger reduction modest, that is expected. There is a longer read on how tirzepatide suppresses appetite that covers the pharmacology in more depth, including why individual response varies.

For some people the effect is pronounced from the first pen. For others it comes on gradually. Neither pattern means something has gone wrong.

What is actually driving the appetite change

Tirzepatide is a dual GIP and GLP-1 receptor agonist used as an appetite suppressant, made by Eli Lilly and sold in the UK as Mounjaro. Both receptors are involved in how the body responds to eating. GLP-1 (glucagon-like peptide-1) slows gastric emptying and sends satiety signals to the hypothalamus. GIP (glucose-dependent insulinotropic polypeptide) has complementary effects on fat metabolism and may amplify the GLP-1 signal. Activating both pathways together appears to produce a stronger appetite effect than targeting either alone.

Gastric emptying slowing is the part people feel most concretely: food stays in the stomach longer, which extends the physical sensation of fullness. At the same time, the brain's reward response to food (the cue-driven wanting that makes a biscuit tempting even when you are not hungry) can also be blunted. Not eliminated, but quieter. The full picture of how tirzepatide affects appetite covers these central and peripheral effects separately, which is useful if you want more detail.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks in adults with obesity, with smaller but still meaningful reductions at lower doses. Those numbers reflect both appetite suppression and the downstream behaviours it enables, eating less, choosing differently.

What this means day to day: food choices on tirzepatide

Because gastric emptying slows, fatty and very rich meals can cause nausea on tirzepatide, particularly early in treatment or after a dose increase. This is not the medicine punishing you; it is a predictable physiological consequence of food sitting in the stomach longer than usual. Most people find that smaller, lower-fat meals are better tolerated. Protein becomes important precisely because appetite is suppressed: if you are eating significantly less overall, you need what you do eat to work harder.

Hydration matters more than people expect. The reduction in appetite can extend to thirst. Drinking enough water, and keeping up fibre intake, helps manage constipation, one of the more common side effects. For practical guidance on how to eat alongside treatment, this page on eating well on Mounjaro covers protein targets, food choices that ease GI symptoms, and what to do if your appetite drops so far that eating feels difficult.

Separately, it is worth knowing that appetite suppression can wear off or feel reduced between doses, particularly in the days before the next injection is due. If that pattern becomes significant, it is worth discussing with your prescriber before adjusting anything. There is more on why Mounjaro's appetite suppression can wear off between doses and when it warrants clinical review.

When the appetite suppression seems insufficient

Not everyone gets the same degree of appetite reduction, and some people find it less than they expected even at higher doses. Before concluding the medicine is not working, it is worth separating out a few things. Sleep deprivation, chronic stress and certain medicines can all work against appetite regulation. The timing of meals and the types of food eaten can reduce or amplify the effect. And sometimes the perceived lack of suppression is actually tolerance to a lower dose that has been static for longer than the titration schedule intended.

If genuine lack of response persists, a prescriber needs to assess why, not a forum or a general search. The page on appetite suppression not working on Mounjaro outlines the most common reasons and when to contact your clinical team. For anyone weighing up whether tirzepatide is the right medicine for their situation, our treatment overview compares the options. Tirzepatide is a prescription-only medicine; suitability is determined through clinical assessment, not BMI alone. If you would like that assessment, the next step is a free consultation with our prescribers.